Although IgE-mediated mast cell activation is the major pathogenic mechanism of chronic spontaneous urticaria (CSU), appreciable numbers of CSU patients are refractory to Omalizumab treatment. Recent two clinical trials with YH35324, a long-acting high-affinity IgETrap-Fc protein demonstrated that YH35324 could remarkably suppress serum-free IgE levels in atopic subjects. Moreover, in CSU patients who are refractory to anti-histamines, YH35324 could achieve better symptom controls compared to Omalizumab. This study aimed to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of YH35324 in patients with CSU refractory to Omalizumab (the part 2 of NCT05960708).
Nine CSU patients refractory to Omalizumab were randomized (2:1) in a double-blind manner to receive a single subcutaneous dose of either YH35324 at 6 mg/kg or placebo, followed by an 8-week observation period. Weekly Urticaria Activity Score (UAS7) and treatment emergent adverse events (TEAEs) were assessed for 8 weeks. Changes in drug concentration and serum-free IgE levels were analyzed.
There were no significant differences in clinical characteristics identified between the two study groups. The single SC dose of YH35324 at 6 mg/kg rapidly reduced disease activity, as evidenced by a median change in UAS7 from baseline of -9.50 at week 1. 50.0% of subjects in the YH35324 group showed complete control (UAS7=0) compared to 33.3% in the placebo group for 8 weeks. These improvements in urticaria symptoms were further supported by a significant reduction in serum-free IgE levels with YH35324 treatment compared to placebo, with sustained suppression throughout the 8-week observation period. PK of YH35324 was consistent with those observed in previous studies. One or more TEAEs were reported in 3 of the subjects (50.0%) in the YH35324 group and 2 (66.7%) of those in the placebo group; no serious or drug-related TEAEs were noted in the YH35324 group.
YH35324 demonstrated clinically meaningful symptom control in CSU patients refractory to Omalizumab, highlighting its therapeutic potential for this population.